Mgi Pharma — CSFB Healthcare Conference 2004
24 slides from Mgi Pharma's conference presentation, Nov 17, 2004
Slide 1: MGI PHARMA, INC. Presented at the CSFB Healthcare Conference
MGI PHARMA, INC. Presented at the CSFB Healthcare Conference November 17, 2004
Slide 2: Forward-Looking Statements
This presentation contains forward- looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission filings. Forward-Looking Statements
Slide 3: Mission & Strategy
MGI PHARMA Mission & Strategy MGI PHARMA is an oncology- focused biopharmaceutical company We acquire, develop and commercialize proprietary pharmaceutical products that address patient needs
Slide 4: Building a leading biopharmaceutical company
MGI PHARMA Building a leading biopharmaceutical company Marketed products & development pipeline Four marketed oncology products Five phase 3 programs planned for 2005 Business development capabilities Five transactions completed in the last 12 months Financial strength Over $280 million of cash and
Slide 5: Building an Oncology Franchise
MGI PHARMA Building an Oncology Franchise Marketed products Development pipeline Dacogen™ injection (AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation ZYC101a (cervical dysplasia) Irofulven (HRPC) ZYC300 (solid tumors)
Slide 6: Aloxi Injection: Best-In-Class 5-HT3 antagonist for CINV
AloxiTM Injection Best-In-Class 5-HT3 antagonist for CINV Approved for both acute and delayed chemotherapy-induced nausea & vomiting (CINV) Favorable head-to-head trials Strong binding affinity (potency) Long half-life Extended activity Obtained exclusive U.S. & Canadian rights for CINV and PONV fro
Slide 7: Aloxi Launch Success October 2003 thru September 2004
Aloxi® Launch Success October 2003 thru September 2004 Monthly IV Units (CINV) Reported by IMS 0.0 50.0 100.0 150.0 200.0 250.0 Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep (000’s) ALOXI ZOFRAN ANZEMET KYTRIL
Slide 8: Kadian
Kadian® Morphine sulfate sustained release capsules 3 year promotion agreement from Alpharma for oncology pain Indicated for management of moderate to severe pain where treatment with an opioid analgesic is indicated for more than a few days Oncology launch by MGI PHARMA in September 2004 Promotion
Slide 9: Building an Oncology Franchise
MGI PHARMA Building an Oncology Franchise Marketed Products Products in Development Dacogen™ injection (MDS) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation ZYC101a (cervical dysplasia) Irofulven (HRPC) ZYC300 (solid tumors)
Slide 10: MGI PHARMA Development Pipeline
Preclinical Phase 1 Phase 2 Phase 3 FDA Review Market MGI PHARMA Development Pipeline Dacogen™ (MDS) Saforis™ (oral mucositis) ZYC101a (cervical dysplasia) Aloxi® Injection (PONV) Aloxi® oral formulation Irofulven Monotherapy Combination Therapy ZYC300 (solid tumors) MG98 Other Acylfulvene Analogs
Slide 11: Dacogen injection
Dacogen™ injection Anti-cancer agent with broad clinical activity Obtained WW rights in Q304 Phase 3 trial in Myelodysplastic Syndromes (MDS) complete MAA submission accepted for review by EMEA NDA submitted American Society of Hematology (ASH): 18 abstracts Full phase 3 MDS data set 3-arm dosing tr
Slide 12: MGI PHARMA Development Pipeline
Preclinical Phase 1 Phase 2 Phase 3 FDA Review Market MGI PHARMA Development Pipeline Dacogen™ (MDS) Saforis™ (oral mucositis) ZYC101a (cervical dysplasia) Aloxi® Injection (PONV) Aloxi® oral formulation Irofulven Monotherapy Combination Therapy ZYC300 (solid tumors) MG98 Other Acylfulvene Analogs
Slide 13: Saforis oral suspension
Saforis™ oral suspension Phase 3 candidate for oral mucositis Obtained through acquisition of Aesgen Proprietary formulation of L-glutamine One phase 3 trial complete in solid tumor (breast cancer) regimens Primary endpoint met (p=0.026): overall 22% risk reduction (WHO>2) vs. placebo Significant ac
Slide 14: MGI PHARMA Development Pipeline
Dacogen™ (MDS) Saforis™ (oral mucositis) ZYC101a (cervical dysplasia) Aloxi® Injection (PONV) Aloxi® oral formulation Irofulven Monotherapy Combination Therapy ZYC300 (solid tumors) MG98 Other Acylfulvene Analogs Preclinical Phase 1 Phase 2 Phase 3 FDA Review Market MGI PHARMA Development Pipeline
Slide 15: ZYC101a
ZYC101a Immunotherapeutic for cervical dysplasia Obtained through acquisition of Zycos (now MGI PHARMA Biologics) Immune response therapeutic for treatment of cervical dysplasia, a precancerous condition Phase 2 study completed in 161 patients: In a prospectively defined population of patients under
Slide 16: MGI PHARMA Development Pipeline
Preclinical Phase 1 Phase 2 Phase 3 FDA Review Market MGI PHARMA Development Pipeline Dacogen™ (MDS) Saforis™ (oral mucositis) ZYC101a (cervical dysplasia) Aloxi® Injection (PONV) Aloxi® oral formulation Irofulven Monotherapy Combination Therapy ZYC300 (solid tumors) MG98 Other Acylfulvene Analogs
Slide 17: Aloxi Injection: Post operative nausea & vomiting (PONV)
Aloxi® Injection Post operative nausea & vomiting (PONV) PONV is a common consequence of anesthetic and surgical procedures >40M surgical procedures annually in the U.S. Prevalent in abdominal, gynecological, and ear, nose and throat surgeries Incidence of PONV estimated at 25% to 30% ~ 30 million d
Slide 18: MGI PHARMA Development Pipeline
Preclinical Phase 1 Phase 2 Phase 3 FDA Review Market MGI PHARMA Development Pipeline Dacogen™ (MDS) Saforis™ (oral mucositis) ZYC101a (cervical dysplasia) Aloxi® Injection (PONV) Aloxi® oral formulation Irofulven Monotherapy Combination Therapy ZYC300 (solid tumors) MG98 Other Acylfulvene Analogs
Slide 19: Irofulven
Irofulven A novel, broadly active cytotoxic New chemotherapeutic class Novel mechanism of action Activity independent of P53 and bcl-2 status Monotherapy activity in prostate, liver, ovarian and pancreatic cancers Combination activity in prostate, colorectal and thyroid cancers Strong patent positio
Slide 20: FY 2004 Financial Guidance
Aloxi injection sales of $150 to $155 million Other product sales of approx. $30 million Licensing revenue of approximately $3 million Cost of product sales as a percent of sales revenue of approximately 32% SG&A expenses of approximately $73 million R&D expenses of approx. $59 million Includes $32
Slide 21: FY 2005 Financial Guidance
FY 2005 Financial Guidance As provided on October 13, 2004 Total revenues of approx. $280 million 1,2 Total operating expenses of $205 million EBIT of $75 million Product candidates acquired and announced on September 1, 2004 could add $500 million in combined net sales to revenue 3 to 4 years after
Slide 22: Balance Sheet
Balance Sheet (in thousands) Shares Outstanding2 Cash and Unrestricted Marketable Investments1 Total Shareholders’ Equity Total Assets Actual September 30, 2004 $281,954 $434,626 Long-term Debt $260,174 $110,609 70,799 1. Excludes equity investments 2. Excludes approx. 10 (5 using the treasury stock
Slide 23: Maximize commercial potential of Aloxi injection
Maximize commercial potential of Aloxi injection in the $1 billion CINV market Leverage sales force by launching in-licensed, acquired and co-promoted products Advance the development of clinical product candidates, including: Dacogen injection Saforis oral suspension Aloxi injection for PONV Aloxi
Slide 24: Building a Leading Biopharmaceutical Company
Building a Leading Biopharmaceutical Company